title: Comparison of dipyridamole and fosinopril on renal progression in nephrectomized rats.
abstract: There is evidence to suggest that antiplatelet aggregation and inhibition of angiotensin converting enzyme will attenuate the progression of renal disease. In the present study, dipyridamole (DPM; 30 mg/kg per day, p.o.) or fosinopril (FOS; 20 mg/kg per day, p.o.) was given to rats for 5 weeks starting immediately after renal mass reduction (right uninephrectomy and ligation of approximately two-thirds of the blood supply to the left kidney). Renal mass reduction caused increased mean arterial blood pressure, reduced effective renal plasma flow (ERPF) and glomerular filtration rate (GFR), azotemia and proteinuria. Neither proteinuria nor hypertension was affected by DPM, although renal function improved markedly. Rats receiving FOS showed normalization of blood pressure with a significant increase in both ERPF and GFR, along with a lower degree of proteinuria. A histological examination of the remnant kidney detected the presence of vasodilation with a lower degree of podocyte swelling in both treatment groups, with a remarkable effect in the FOS group. These data indicate that both FOS and DPM attenuate the progression of glomerular disease associated with renal mass reduction in rats. However, FOS was more beneficial than DPM because it reduced proteinuria and lowered blood pressure.
authors.affiliation: Department of Physiology, Faculty of Veterinary Science, Chulalongkorn University, Bangkok, Thailand. bchollad@chula.ac.th
authors.forename: Chollada
authors.initials: C
authors.lastname: Buranakarl
authors.forename: Anusak
authors.initials: A
authors.lastname: Kitjtawonrat
authors.forename: Somchai
authors.initials: S
authors.lastname: Pondeenana
authors.forename: Boonmee
authors.initials: B
authors.lastname: Sunyasujaree
authors.forename: Sumolaya
authors.initials: S
authors.lastname: Kanchanapangka
authors.forename: Narongsak
authors.initials: N
authors.lastname: Chaiyabutr
authors.forename: Kenneth C
authors.initials: KC
authors.lastname: Bovee
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000818:Animals; D004176:Dipyridamole / Q000627:therapeutic use*; D018450:Disease Progression; D017328:Fosinopril / Q000627:therapeutic use*; D008297:Male; D009392:Nephrectomy; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D051437:Renal Insufficiency / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D010975:Platelet Aggregation Inhibitors; D004176:Dipyridamole; D017328:Fosinopril